Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.38, $0.09 worse than the analyst estimate of $1.47. Revenue for the quarter came in at $36.3 million versus the consensus estimate of $3.41 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.